Search
for
Sort by
Research 30 of 1000+
- Cutaneous adverse effects of targeted therapies
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Mathematical Modeling and Inference of Epidermal Growth Factor-Induced Mitogen-Activated Protein Kinase Cell Signaling Pathways
- 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
- Exosomes derived from Umbilical cord mesenchymal stem cell promote hair regrowth in C57BL6 mice through upregulation of the RAS/ERK signaling pathway
- Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARα and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways
- B-Raf and C-Raf Are Required for Melanocyte Stem Cell Self-Maintenance
- Exploiting the origins of Ras mediated squamous cell carcinoma to develop novel therapeutic interventions
- Acute sensitivity of the oral mucosa to oncogenic <i>K‐ras</i>
- Regulation and Role of GLI1 in Cutaneous Squamous Cell Carcinoma Pathogenesis
- VEGF upregulates VEGF receptor-2 on human outer root sheath cells and stimulates proliferation through ERK pathway
- 12-O-Tetradecanoylphorbol-13-acetate Induces Apoptosis in Renal Epithelial Cells through a Growth Signal Conflict Which Is Prevented by Activated ras1
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
- Trichosanthes kirilowii Extract Promotes Wound Healing through the Phosphorylation of ERK1/2 in Keratinocytes
- Hair growth potential of <i>Salvia plebeia</i> extract and its associated mechanisms
- HNG, A Humanin Analogue, Promotes Hair Growth by Inhibiting Anagen-to-Catagen Transition
- Insulin-like Growth Factor 1 (IGF-1) in Hair Regeneration: Mechanistic Pathways and Therapeutic Potential
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Pre‐clinical evidences for the efficacy of tryptanthrin as a potent suppressor of skin cancer
- Reductive Stress Selectively Disrupts Collagen Homeostasis and Modifies Growth Factor-independent Signaling Through the MAPK/Akt Pathway in Human Dermal Fibroblasts
- Thymosin Beta-4 Induces Mouse Hair Growth
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities
- Stem cells and aberrant signaling of molecular systems in skin aging
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)